Table 1.
Demographics.
| Age (mean, range) | 15.4 years (5–21 years) |
| Sex (N, % male) | 23 (62.2%) |
| Race (N, %) | |
| White | 27 (73%) |
| Black/African American | 3 (8.1%) |
| Asian | 2 (5.4%) |
| American Indian/Alaska Native | 1 (2.7%) |
| Multiracial | 2 (5.4%) |
| Unknown | 2 (5.4%) |
| Ethnicity (N, %) | |
| Hispanic/Latino | 3 (8.1%) |
| Non-Hispanic/Latino | 28 (75.7%) |
| Unknown/Other | 6 (16.2%) |
| Medical History (N, %) | |
| Kidney transplant | 12 (32.4%) |
| Liver transplant | 5 (13.5%) |
| Stem cell transplant | 1 (2.7%) |
| Rheumatologic disease | 13 (35.1%) |
| Gastrointestinal disease | 6 (16.2%) |
| Immunosuppressive medications (N) | |
| Tacrolimus, Mycophenolate mofetil, Prednisone | 11 |
| Methotrexate, Adalimumab/Infliximab | 6 |
| Adalimumab or Infliximab | 6 |
| Tacrolimus | 3 |
| Methotrexate | 2 |
| Sirolimus | 2 |
| Hydrocortisone/Stem cell transplant | 1 |
| Sirolimus, Mycophenolate mofetil, Prednisone | 1 |
| Rituximab | 1 |
| Anakinra, Infliximab | 1 |
| Cellcept, Prednisone | 1 |
| Tocilizumab | 1 |
| Abatacept | 1 |
| Self-reported COVID-19 Illness Prior to 3rd Vaccine (N, %) | |
| Yes | 6 (16.2%) |
| No | 29 (78.4%) |
| Unknown | 2 (5.4%) |
| Months between 2nd and 3rd COVID vaccine (mean, range) | 4.38 months (1–9 months) |